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Poster Session I S203(MM) and lymphoma (L) undergoing first SCM that used G (10
mcg/kg without dose escalation) and non-mobilizers had a maxi-
mum of 4 days of P.
Results: Among CY +G pts, 141 (61%) were males; 121 (50%) had
MM, 115 (48%) had L (5-other diagnoses); 61 (25%) pts. had prior
radiation. PCOwas seen in 48 (20%) pts., 23% ofMM and 15.7% of
L pts. Mean total cost of CY +G SCM was $10,732 (range, 6988-
30827). PCO was associated with a lower cost than non-PCO in
the overall group, (mean, $10,371 vs. $12,870, P5 0.001), in MM
pts. (mean, $10,511 vs. $12,152, P5 0.026), and in L pts (mean,
$10,133 vs. $13,627, P5 0.006). Assuming a similar distribution of
PCO in 100 pt. with MM and L, the projected per pt cost of SCM
would be $11,774 and $13,067 (mean, $12,421) with CY +G. Pro-
jected costs of SCM using P +G for 100 pts. with MM and L were
$12,852 and $8986 (mean, $10,919).
Conclusion: SCM with CY +G was associated with a lower rate of
PCO and higher cost than P +G. This comparision is limited by dif-
ferent sources of patient data, only the CY +G data was ‘‘real world’’,
and only product-related costs were examined. This study represents
an important initial step towards informing cancer management
based on a profile of outcomes that compare relevant therapeutic al-
ternatives.122
PLERIXAFOR PLUS G-CSF RESULTED IN SIMILAR COST BUT MORE PRE-
DICTABLE DAYS OF APHERESIS COMPARED TO CHEMOTHERAPY PLUS G-
CSF FOR MOBILIZATION OF AUTOLOGOUS HEMATOPOIETIC STEM CELLS
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Plerixafor plus G-CSF has been shown to mobilize more
CD34+ cells than G-CSF alone for autologous hematopoietic
stem cell transplant (HSCT). However, many centers use chemo-
therapy (chemo) followed by G-CSF to mobilize CD34+ cells
prior to HSCT. We performed a retrospective study of pts
who participated in the expanded access program (EAP) of pler-
ixafor/G-CSF for upfront mobilization of CD34+ cells, and com-
pared outcomes to matched historical controls mobilized with
chemo/G-CSF at two centers that participated in the study. Con-
trol pts were matched for age, sex, disease stage, and number of
prior therapies. Control pts received cyclophosphamide 3-5 gm/
m2 followed by daily G-CSF. Study pts received G-CSF 10
mcg/kg daily for 5 days and plerixafor 0.24 mg/kg was given
on the evening of day 4, twelve hours before apheresis on day
5. Mobilization costs were considered to be the costs of medical
procedures, resource utilization and medications. Median national
CMS reimbursement rates were used to evaluate the costs of pro-
cedures, hospitalization, provider visits, apheresis, CD34+ cell
processing and cryopreservation. Average sale price was used
for G-CSF, plerixafor, cyclophosphamide, mesna, antiemetics
and antimicrobials. A total of 34 patients from EAP and 34
matched controls were studied. Comparison of the number of
doses of G-CSF, number of apheresis, total CD34+ cells col-
lected, and cost is given in the table. Two pts in the control
group were hospitalized for neutropenic fever during the mobili-
zation period after receiving chemo. Apheresis started on the
scheduled day in 27 (79%) study pts and in 18 (53%) control
pts (p5 0.021). Unplanned starts of apheresis resulted in 17
(50%) control pts undergoing weekend apheresis. Study pts re-
ceived a median of 1 dose of plerixafor (median 16.9 mg), and
the average sale price for plerixafor in this analysis was $6,250
per 24 mg/vial. All pts proceeded to HSCT with no difference
in outcomes. In conclusion, plerixafor/G-CSF compared to
chemo/G-CSF for upfront mobilization of CD34+ cells resulted
in similar number of cells collected, cost of mobilization, and
clinical outcomes. However, plerixafor/G-CSF mobilization re-
sulted in more predictable days of collection, no weekend apher-esis procedures, and no unscheduled hospital admissions. Higher
acquisition cost of plerixafor was offset by less G-CSF use and
less resource utilization compared to cyclophosphamide based
mobilization.
Cost and Resource Comparison
All values median(range) Plerixafor/GCSF Chemo/GCSF p valueG-CSF dose 780ug (600-1440) 900ug (480-1260) 0.9No. G-CSF doses 5 (4-8) 10 (6-17) 0.0001Apheresis days 1 (1-4) 1 (1-4) 0.33Total CD34 cells
(million/kg)11.1 (3.5-37.9) 11.2 (2.1-69.3) 0.86Un-scheduled
hospital days0 2 0.0001Weekend




EFFICACY OF PLERIXAFOR PLUS G-CSF IN HEMATOPOIETIC STEM CELL
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Introduction: High-dose melphalan and autologous HSC trans-
plantation produces the highest remission rate for patients (pts)
with amyloidosis. HSC mobilization/collection is challenging in
these patients, particularly those with cardiac involvement with re-
ported increased morbidity and even mortality. Thus, agents that
can mobilize stem cells safely, efficiently and effectively would be
beneficial in these patients. This retrospective analysis evaluated
the efficacy and safety of plerixafor + G-CSF (P +G) remobilization
in amyloidosis pts.
Methods: Pts with amyloidosis unable to collect $2106 CD34+
cells/kg in prior attempts were remobilized with P +G in a compas-
sionate use program (CUP). G-CSF (10 mg/kg SC) was given every
morning for 5 days. Plerixafor (0.24 mg/kg SC) was given in the
evening on Day 4,11 hours prior to apheresis the next day. Plerix-
afor, G-CSF and apheresis were repeated daily until pts collected
$2106 cells/kg.
Results:Of 1011 pts in the plerixafor CUP database, 11 pts were re-
ported to have amyloidosis. In prior mobilization attempts, 3 pts col-
lected 0.8, 0.17 and 0.9106 CD34+ cells/kg and in 8 pts, collection
was not attempted due to low circulating peripheral blood CD34+
cell numbers. Remobilization with P +G resulted in a median yield
of 6.6106 cells/kg; 10/11 pts collected the minimum target of
2106 cells/kg and 7/11 pts reached the optimal target of $5106
cells/kg with the majority (10/11) collecting the minimum cell
dose in 1 or 2 apheresis days. Ten pts went to transplant; median
time to platelet and neutrophil engraftment was 19 and 14 days, re-
spectively. Drug-related adverse events were experienced by 5 pts
during mobilization and collection and included injection site reac-
tions (5), nausea (2), diarrhea (2), headache (1), hyperuricemia (1),
hypokalemia (1), paraesthesias (1) and QT prolongation on electro-
cardiogram (1). The patient with the prolongedQT interval had car-
diac amyloidosis and hypokalaemia. This patient died approximately
1 month after mobilization and collection, of cardiac arrest not re-
lated to plerixafor.
Conclusion: These results provide preliminary evidence that P +G
can safely and effectively remobilize HSC in amyloidosis pts who
S204 Poster Session Ihave failed prior mobilization with G-CSF 6 chemotherapy. The
minimum and optimal cell dose for transplant was collected in
91% and 64% of the patients, respectively. Future studies should ex-
plore the safety and efficacy of P +G in front-line mobilization of
amyloidosis pts.
Table 1. Remobilization OutcomesNo. of Patients 11
Median age (range) 61 (48-73)
Gender, male (%) 10 (90.9)
Median CD341Cells/kg x 106 Collected
(range)
6.61 (1.63-17.67)No. of patients collecting $2 x 106 CD341
cells/kg (%)10 (90.9)No. of patients collecting $5 x 106 CD341
cells/kg (%)7 (63.6)No. of patients proceeding to transplant (%) 10 (90.9)
Median days to platelet engraftment (range) 19 (7-25)
Median days to neutrophil engraftment (range) 14 (6-27)124
G-CSF+/- PLERIXAFOR IS SUPERIOR TO CYCLOPHOSPHAMIDE + G/GM-
CSF FOR AUTOLOGOUS HEMATOPOIETIC STEM CELLS (AHSC) MOBILIZA-
TION
Miller, A.N., Hogan, K.R., Alexander, E., Schaub, C., Fouts, T.,
Stuart, R.K., Costa, L.J. Medical University of South Carolina, Charles-
ton, SC
Background:The idealmethod tomobilize AHSC is unknown. The
use of chemotherapy (mostly cyclophosphamide) + growth factors,
when compared with the use of growth factors only, has the advan-
tage of higher HSC yield and fewer mobilization failures but is asso-
ciated with more complications. The use of the CXCR-4/SDF-1
binding inhibitor plerixafor, added to growth factor, may overcome
the limitations to the use of growth factor mobilization without che-
motherapy
Methods: We have developed a cost-saving decision making algo-
rithm that utilizes the CD34+ count in the peripheral blood on the
4th day of G-CSF administration (PB-CD34+) and the target
CD34+ count for the specific patient (T-CD34+) to decide between
starting collection on day 4 and continuing G-CSF administration
only (G approach) or adding Plerixafor the night before each apher-
esis session and starting apheresis on day 5 (G + P approach) (MUSC
algorithm, presented at 2010 tandemmeeting).We compared the ef-
ficacy of AHSCmobilization for patients with lymphoma ormultiple
myeloma utilizing theMUSC algorithm (MA cohort) with an histor-
ical series of patients undergoing mobilization with cyclophospha-
mide 2000 mg/m2 followed by G-CSF and/or GM-CSF (CY
cohort).
Results: Overall 28 individuals (9 on G and 19 on G + P) are in-
cluded in MA and 81 in CY. Patient’s characteristics are displayed
in table 1. The mobilization failure rate was 0% in MA vs. 22% in
CY (P5 0.01). Of the 18 patients who failed mobilization in CY,
10 completed collection in a subsequent mobilization attempt.
None of patients in MA and 4 patients in CY had infectious compli-
cations requiring hospitalization during mobilization. Patients com-
pleting collection in MA had in average 1.68 days of apheresis, vs.
1.73 in CY (P5 n.s.). The median yield of CD34+/kg was 6.4 
106 (range 3-15.8) in MA vs. 7.7  106 (range 2.8-72.6) in CY
(P5 0.07). For the 19 patients in MA and 60 in CY who received
a first autologous transplant, the median interval between beginning
of mobilization and transplant D0 was 13 days (range 11-63) and 42
days (range 12-157) respectively (P\0.01). There were no differ-
ences between MA and CY approaches in time for absolute neutro-
phil count. 500/mm2 (median 12 days for both MA and CY) or
platelet count. 20,000/mm2 without platelet transfusion (median
12 days for both MA and CY).Conclusion:TheMUSCmobilization algorithm is reliable and pro-
vides faster and safer mobilization than the use of cyclophosphamide
+ growth factor.
Table 1. Characteristics of the patients
MA- N5 28 CY- N5 81Diagnosis
Multiple Myeloma 23 (82%) 33 (41%)
Lymphoma 5 (18%) 48 (59%)
Age
#60 17 (61%) 49 (60%)
.60 11 (39%) 32 (40%)Gender
Male 10 (36%) 42 (52%)
Female 18 (64%) 39 (48%)
Prior radiation 10 (36%) 14 (17%)Prior lines of therapy- Lymphomas
#2 5 (100%) 40 (83%)
.2 0 (0%) 8 (17%)Prior lines of therapy- Myeloma
1 10 (43%) 13 (39%)
.1 13 (57%) 20 (61%)Prior lenalidomide 14 (61%) 7 (21%)125
PHASE I STUDY OF VORINOSTAT (SAHA) AFTER AUTOLOGOUS TRANS-
PLANT FOR PATIENTS WITH HIGH RISK LYMPHOMA
Hofmeister, C.C., Lozanski, G., Baiocchi, R.A., Hade, E.M.,
Benson, D.M., Blum, K., Porcu, P., Byrd, J.C., Devine, S.M. The Ohio
State University, Columbus, OH
Only the minority of patients with high risk or high intermediate
risk lymphoma will be cured with autologous transplant. SAHA has
shown activity in relapsed lymphoma and there is preclinical evi-
dence that HDACs may render lymphoma cells more susceptible
to host immune killing.
Methods:The primary objective was to assess safety and tolerabil-
ity of SAHA after BEAM-conditioned autologous transplant start-
ing day +60 for 21 consecutive days of a 28-day cycle for up to 11
cycles with 4 cohorts 100-400 mg of SAHA daily. Secondary ob-
jectives included preliminary clinical activity, NK and Treg recov-
ery, response to Prevnar vaccination at cycles 1/3/5, and quality of
life data (CES-D, BFI, and FACT-G). Patients were eligible with
DLBCL (induction failure, stage III/IV at relapse, age. 60, or el-
evated LDH at relapse), FL (transformed or 2+ prior regimens),
HL (primary refractory or PET positive after salvage), MCL, or
T-cell NHL.
Results: 10 lymphoma patients (median age 59 y.o, range 25-75)
have been treated thus far with FL (1), MCL (4), NS-HL (1),
PTCL (2), ALK-1 negative ALCL (1), and angioimmunoblastic
T-cell (1). Two pts had a PR after salvage chemotherapy pre-trans-
plant while the remaining 8 were in a CR. All patients were in a CR
post transplant and three patients (200 mg SAHA cohort) have suf-
fered progressive disease (1 after cycle 10, 1 after cycle 3, and 1 after
cycle 1). Drug-related adverse events consisted of two episodes of
grade 4 neutropenia (neither was dose-limiting), two patients suf-
fered grade 3 neutropenia, two with grade 3 rash/pruritus, and one
with grade 3 anorexia which was dose-limiting. The other DLT
was persistent grade 2 neutropenia thought to be clinically signifi-
cant. Preliminary analysis of peripheral blood flow cytometry
(n5 6) obtained at the beginning of odd numbered cycles showed
that patients with progressive disease had decreases over time in
the%of late activatedCD3 +HLA-DR+ andCD3 +CD86 +T-cells
with increased CD3 +CD16 + CD56dim NKT cells and
CD4 +CD25 + CD127- Tregs.
Conclusion:This ongoing phase I study of SAHA is accruing at the
300 mg SAHA dose level and has more neutropenia in the post auto-
graft population. Additional flow cytometry and quality of life data
